Ardent Health, Inc. filed a Form 8-K on November 19, 2026, disclosing a secondary stock offering by two selling stockholders and a concurrent share repurchase by the company that closed the same day.

Key Highlights

  • Secondary offering size: EGI-AM Investments, L.L.C. and ALH Holdings, LLC sold 8,000,000 shares of common stock at a public offering price of $14.50 per share.
  • No company proceeds: According to the filing, Ardent Health, Inc. did not receive any proceeds from the sale of shares by the Selling Stockholders.
  • Concurrent repurchase: The company repurchased 1,500,000 shares from the Underwriters at $13.7025 per share, funded with existing cash on hand.
  • Overallotment option: The Selling Stockholders granted the Underwriters a 30-day option to purchase up to an additional 1,200,000 shares at the public offering price, less underwriting discounts and commissions.
  • Existing repurchase program unaffected: The filing states the concurrent repurchase was not made pursuant to the company's previously disclosed stock repurchase program and does not reduce the approximately $48.0 million of remaining repurchase authorization thereunder.
  • Underwriting representatives: J.P. Morgan Securities LLC and Barclays Capital Inc. served as representatives of the several underwriters named in the Underwriting Agreement.

Secondary Offering and Share Repurchase Details for Ardent Health

According to the Form 8-K filed with the SEC, Ardent Health, Inc. (NYSE:ARDT) disclosed that on November 17, 2026, the company and its two selling stockholders, EGI-AM Investments, L.L.C., an affiliated entity of Equity Group Investments, and ALH Holdings, LLC, a subsidiary of Ventas, Inc., entered into an Underwriting Agreement with J.P. Morgan Securities LLC and Barclays Capital Inc. as representatives of the underwriters. The agreement covered the sale of 8,000,000 shares of common stock, par value $0.01 per share, at a public offering price of $14.50 per share. The offering closed on November 19, 2026.

The filing noted that the company received none of the proceeds from the offering, as all shares were sold by the Selling Stockholders. In connection with the offering, the Selling Stockholders also granted the Underwriters a 30-day option to purchase up to 1,200,000 additional shares at the public offering price, less underwriting discounts and commissions.

Separately, the filing disclosed that also on November 19, 2026, Ardent Health repurchased 1,500,000 shares of common stock from the Underwriters at a purchase price of $13.7025 per share, described as the price at which the Underwriters purchased the shares from the Selling Stockholders. The company reported using existing cash on hand for this concurrent share repurchase. The filing stated that the Underwriters received no compensation for the repurchased shares, and that this repurchase was distinct from and does not reduce the approximately $48.0 million remaining under the company's previously disclosed stock repurchase program. The offering was conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-289763) declared effective on August 25, 2025.

What Was Disclosed

Ardent Health, Inc. reported a secondary offering of 8,000,000 shares by two affiliated selling stockholders at $14.50 per share, alongside a concurrent company repurchase of 1,500,000 shares at $13.7025 per share using cash on hand, with the company receiving no offering proceeds.